Author:
Sam Tom,Bastiaansen Marc,Gordon Keith
Publisher
Springer International Publishing
Reference25 articles.
1. Balen AH, Mulders AG, Fauser BC, Schoot BC, Renier MA, Devroey P et al (2004) Pharmacodynamics of a single low dose of long-acting recombinant follicle- stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. J Clin Endocrinol Metab 89(12):6297–6304
2. De Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L (1996) Structure-function relationship of recombinant follicle stimulating hormone (Puregon®). Mol Hum Reprod 2:361–369
3. Devroey P, Boostanfar R, Koper NP, Ijzerman P, Mannaerts BMJL, Fauser BC, for the ENGAGE Investigators (2009) A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 24:3063–3072
4. EMA (2006) European Public Assessment Report Puregon (Follitropin beta) https://www.ema.europa.eu/en/documents/product-information/puregon-epar-product-information_en.pdf. Accessed 16 Mar 2022
5. EMA (2010) European Public Assessment Report Gonal-F (Follitropin alfa) https://www.ema.europa.eu/en/documents/product-information/gonal-f-epar-product-information_en.pdf. Accessed 16 Mar 2022